Biased allosteric agonism and modulation of metabotropic glutamate receptor 5: Implications for optimizing preclinical neuroscience drug discovery
- PMID: 27392634
- PMCID: PMC5217481
- DOI: 10.1016/j.neuropharm.2016.07.001
Biased allosteric agonism and modulation of metabotropic glutamate receptor 5: Implications for optimizing preclinical neuroscience drug discovery
Abstract
Allosteric modulators, that exhibit no intrinsic agonist activity, offer the advantage of spatial and temporal fine-tuning of endogenous agonist activity, allowing the potential for increased selectivity, reduced adverse effects and improved clinical outcomes. Some allosteric ligands can differentially activate and/or modulate distinct signaling pathways arising from the same receptor, phenomena referred to as 'biased agonism' and 'biased modulation'. Emerging evidence for CNS disorders with glutamatergic dysfunction suggests the metabotropic glutamate receptor subtype 5 (mGlu5) is a promising target. Current mGlu5 allosteric modulators have largely been classified based on modulation of intracellular calcium (iCa2+) responses to orthosteric agonists alone. We assessed eight mGlu5 allosteric modulators previously classified as mGlu5 PAMs or PAM-agonists representing four distinct chemotypes across multiple measures of receptor activity, to explore their potential for engendering biased agonism and/or modulation. Relative to the reference orthosteric agonist, DHPG, the eight allosteric ligands exhibited distinct biased agonism fingerprints for iCa2+ mobilization, IP1 accumulation and ERK1/2 phosphorylation in HEK293A cells stably expressing mGlu5 and in cortical neuron cultures. VU0424465, DPFE and VU0409551 displayed the most disparate biased signaling fingerprints in both HEK293A cells and cortical neurons that may account for the marked differences observed previously for these ligands in vivo. Select mGlu5 allosteric ligands also showed 'probe dependence' with respect to their cooperativity with different orthosteric agonists, as well as biased modulation for the magnitude of positive cooperativity observed. Unappreciated biased agonism and modulation may contribute to unanticipated effects (both therapeutic and adverse) when translating from recombinant systems to preclinical models. This article is part of the Special Issue entitled 'Metabotropic Glutamate Receptors, 5 years on'.
Keywords: Biased agonism; CDPPB (PubChem CID: 11245456); DHPG (PubChem CID: 108001); DPFE (PubChem CID: 16663278); Glutamate (L-glutamic acid PubChem CID: 33032); Metabotropic glutamate receptor 5; Positive allosteric modulator; Stimulus bias; VU0360172 (PubChem CID: 53318624); VU0403602 (PubChem CID: 53384878); VU0405398 (PubChem CID: 70789303); VU0424465 (PubChem CID: 53384864); VU29 (PubChem CID: 11610682).
Copyright © 2016 Elsevier Ltd. All rights reserved.
Figures
Similar articles
-
Probe dependence and biased potentiation of metabotropic glutamate receptor 5 is mediated by differential ligand interactions in the common allosteric binding site.Biochem Pharmacol. 2020 Jul;177:114013. doi: 10.1016/j.bcp.2020.114013. Epub 2020 May 8. Biochem Pharmacol. 2020. PMID: 32389635
-
Differential contribution of metabotropic glutamate receptor 5 common allosteric binding site residues to biased allosteric agonism.Biochem Pharmacol. 2020 Jul;177:114011. doi: 10.1016/j.bcp.2020.114011. Epub 2020 May 5. Biochem Pharmacol. 2020. PMID: 32380090
-
Kinetic and system bias as drivers of metabotropic glutamate receptor 5 allosteric modulator pharmacology.Neuropharmacology. 2019 May 1;149:83-96. doi: 10.1016/j.neuropharm.2019.02.005. Epub 2019 Feb 11. Neuropharmacology. 2019. PMID: 30763654 Free PMC article.
-
Biased agonism and allosteric modulation of metabotropic glutamate receptor 5.Clin Sci (Lond). 2018 Nov 2;132(21):2323-2338. doi: 10.1042/CS20180374. Print 2018 Nov 15. Clin Sci (Lond). 2018. PMID: 30389826 Review.
-
Metabotropic glutamate receptors as therapeutic targets in Parkinson's disease: An update from the last 5 years of research.Neuropharmacology. 2017 Mar 15;115:166-179. doi: 10.1016/j.neuropharm.2016.03.036. Epub 2016 Apr 4. Neuropharmacology. 2017. PMID: 27055772 Review.
Cited by
-
The Impact of LY487379 or CDPPB on eNOS Expression in the Mouse Brain and the Effect of Joint Administration of Compounds with NO• Releasers on MK-801- or Scopolamine-Driven Cognitive Dysfunction in Mice.Molecules. 2024 Jan 29;29(3):627. doi: 10.3390/molecules29030627. Molecules. 2024. PMID: 38338372 Free PMC article.
-
Oscillatory Deficits in the Sub-Chronic PCP Rat Model for Schizophrenia Are Reversed by mGlu5 Receptor-Positive Allosteric Modulators VU0409551 and VU0360172.Cells. 2023 Mar 16;12(6):919. doi: 10.3390/cells12060919. Cells. 2023. PMID: 36980260 Free PMC article.
-
Advances in translating mGlu2 and mGlu3 receptor selective allosteric modulators as breakthrough treatments for affective disorders and alcohol use disorder.Pharmacol Biochem Behav. 2022 Sep;219:173450. doi: 10.1016/j.pbb.2022.173450. Epub 2022 Aug 18. Pharmacol Biochem Behav. 2022. PMID: 35988792 Free PMC article. Review.
-
Conformational fingerprinting of allosteric modulators in metabotropic glutamate receptor 2.Elife. 2022 Jul 1;11:e78982. doi: 10.7554/eLife.78982. Elife. 2022. PMID: 35775730 Free PMC article.
-
Allosteric Molecular Switches in Metabotropic Glutamate Receptors.ChemMedChem. 2021 Jan 8;16(1):81-93. doi: 10.1002/cmdc.202000444. Epub 2020 Aug 25. ChemMedChem. 2021. PMID: 32686363 Free PMC article. Review.
References
-
- Balu DT, Li Y, Takagi S, Presti KT, Ramikie TS, Rook JM, Jones CK, Lindsley CW, Conn PJ, Bolshakov VY, Coyle JT. An mGlu5-Positive Allosteric Modulator Rescues the Neuroplasticity Deficits in a Genetic Model of NMDA Receptor Hypofunction in Schizophrenia. Neuropsychopharmacol. 2016;41:2052–2061. - PMC - PubMed
-
- Bezprozvanny I, Hayden MR. Deranged neuronal calcium signaling and Huntington disease. Biochem Biophys Res Commun. 2004;322:1310–1317. - PubMed
-
- Bridges TM, Rook JM, Noetzel MJ, Morrison RD, Zhou Y, Gogliotti RD, Vinson PN, Xiang Z, Jones CK, Niswender CM, Lindsley CW, Stauffer SR, Conn PJ, Daniels JS. Biotransformation of a novel positive allosteric modulator of metabotropic glutamate receptor subtype 5 contributes to seizure-like adverse events in rats involving a receptor agonism-dependent mechanism. Drug Metab Dispos. 2013;41:1703–1714. - PMC - PubMed
-
- Chen Y, Nong Y, Goudet C, Hemstapat K, de Paulis T, Pin JP, Conn PJ. Interaction of novel positive allosteric modulators of metabotropic glutamate receptor 5 with the negative allosteric antagonist site is required for potentiation of receptor responses. Mol Pharmacol. 2007;71:1389–1398. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Miscellaneous